User:Bob the goodwin/sandbox: Difference between revisions
Line 76: | Line 76: | ||
===High cost and low benefit of treating chronic diseases=== |
===High cost and low benefit of treating chronic diseases=== |
||
The care of individuals with chronic conditions is estimated to account for 78% of health expenditures in the United States and insurance companies have begun to target high cost chronic illness for savings. Future work in computerized treatment decision is needed to anticipate doctors overlooking or overprescribing treatments.[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150598/ Multiple Chronic Conditions: Prevalence, Health Consequences, and Implications for Quality, Care Management, and Costs] |
|||
As early as the 1990's insurance companies used tightened requirements enough to make insurable treatment rare. Insurance companies understood that only certain people would fight for coverage. <ref>Science journalist Pamela Weintraub reported details of Supreme Court of the State of New York hearing in a chapter titled “Red-Flagged at Blue Cross: The Role of Managed Care” in her book “Cure Unknown: Inside the Epidemic.” (pp. 303-306) </ref> |
|||
===Self-treatment trends on the internet=== |
===Self-treatment trends on the internet=== |
Revision as of 23:55, 4 January 2014
My Sandbox is a place where I am going to make statements about the Lyme Wars and the associated medicine that I believe I can support with secondary reliable sources. I may put placeholders in temporarily with the notations (Need Ref), (OR), or (Primary), or (Opinion) where I have incomplete work. Please feel free to comment here or on [User_talk:Bob_the_goodwin My talk page]. Dissent is appreciated. I will not be doing any edits on Wikipedia while the consensus remains that chronic lyme is a fringe opinion. I tested this belief, and believe that is the current consensus. [Talk:International_Lyme_And_Associated_Diseases_Society]. I repeat, the following is NOT a proposed article, nor I am writing this as a way to promote language in Wikipedia. I am writing this to answer questions I have been given by editors.
Summary
The "Lyme Wars" is an ongoing dispute since at least 1993 between mainstream medicine (especially Infectious Diseases Society of America and Centers for Disease Control and Prevention) and a minority set of doctors, scientists and patient activists (especially ILADS).
The two main points of disagreement are
- The mainstream view that Lyme disease is over-diagnosed, and is easily cured with short term antibiotics, and that persistent infection (chronic Lyme disease) does not exist.
- The minority view that the actions of Infectious Diseases Society of America were quasi-regulatory as they controlled research, insurance coverage and participated in enforcement of their Lyme guidelines as mandatory.
There is no objective evidence of the truth of either of the points of disagreement. However the war itself has likely been harmful to public health.
Although a lot of the debate centers on the long term use of antibiotics to treat chronic Lyme disease, much of the most promising research involves accurate detection of the Lyme bacteria, the role and disruption of biofilms, and understanding genetic and other factors in immune response to Lyme infections.
The Lyme Wars may be a Proxy War for larger issues in medicine, including the high cost and low benefit of treating chronic diseases, public information and self-treatment trends on the internet, and pressure on doctor patient relationships and clinical diagnosis.
The Source of the misunderstanding
The "Lyme Wars" grew steadily through the 1980s and 1990s as increasing populations of people presented themselves to doctors with clinical symptoms of Lyme disease and doctors began using longer doses of antibiotics. Allen Steere wrote in 1993, that Lyme disease had become "overdiagnosed" and overtreated.[1]. In 1993, Joeseph Burrascano gave testimony alongside Allen Steere to the Senate, were he asserted that a few researchers discredit opponents to create bias within federal agencies and medical journals in order to promote flawed science. [1]
The reasons that Allen Steere and Gary Wormser initially rejected the concept that would later be commonly called chronic Lyme disease are not known, but there is an explanation for the current thinking within the IDSA guideline for the treatment of Lyme Disease, namely:
- Lyme bacteria does not have antibiotic resistance (presumably in vivo)
- Persistent symptoms of Lyme disease do not correlate with either inflammation or with later objective evidence of disease.
- improbable that chronic B. burgdorferi infection can occur in the absence of antibodies
- The only other Spirochete, Syphilis was easily treated with antibiotics.
- None of the factors exist that allow other infections to survive antibiotics exist with Lyme bacteria, namely:
- Lyme bacteria does not primarily persists in people with compromised immune systems.
- Lyme bacteria are not partially damaged by antibiotics, they are killed
- Available antibiotics are fully effective against Lyme bacteria in vitro.
- Lyme bacteria are not caused by an intracellular pathogen
- Lyme bacteria are not involved within a biofilm
- Lyme bacteria are not on a heart valve.
- Lyme bacteria are not involved in within a ischemia, foreign body, sequestrum, or frank pus.
- Lyme bacteria can survive antibiotic treatment when they are in the cystic form, but these have no clinical significance. no cyst involvement in disease
The debate has taken many forms in the following two decades, but the main points of dispute are
- The Lyme bacteria can evade the immune system. immune evasion by Lyme bacteria
- The Lyme bacteria is involved with biofilm. Eva Sapi discovers Lyme bacteria biofilms
- The cystic (and other forms) are resistant to antibiotics and do revert to clinically significant forms. Polish review
- The bacteria is capable of disrupting the immune system, thus causing the immune system to use different antibodies. not sure, neuro-inflammation by proxy
- There is heart valve involvement. not sure, heart tissue damage
Post-treatment symptoms were postulated to be auto-immune by researchers who dismiss the existence of chronic Lyme.
The two sides
(no references in this section, will come back)
The mainstream medical view of Lyme disease comes from the IDSA Lyme treatment guideline, written by the following authors:
Wormser GP (New York Medical College), Dattwyler RJ (New York Medical College), Shapiro ED (Yale), Halperin JJ (NYU), Steere AC (Harvard), Klempner MS (UMASS), Krause PJ (Yale), Bakken JS(University of Minnesota), Strle F (Slovenia), Stanek G (Austria), Bockenstedt L (Yale), Fish D (Yale), Dumler JS (Johns Hopkins), Nadelman RB (New York Medical College)
The Guideline governs care throughout all western nations. Although nominally the guideline is written as optional, and physicians are licensed by individual states, in practice they limited physicians and patients choices. Insurance companies used the more restrictive IDSA guidelines to limit coverage for chronic Lyme disease (ref needed), and doctors were intimidated by the investigation or sanctioning of 50 physicians for prescribing longer term treatment approaches to Lyme disease. (ref to Blumenthal press release)
Today the minority opinion comes the ILADS in the US, and the German Borreliosis Society in Europe.
Doctors in the US who treat patients using the ILADS protocol are often referred to as 'Lyme Literate Physicians' or LLMD's. ILADS was founded in 1999 by doctors who aggressively treated Lyme disease in response to the polarization, the state actions against Lyme doctors, and the restrictions on insurance coverage for their patients. The organization ultimately expanded into medical research, training of new LLMDs, lobbying states governments to protect the doctor patient relationship, drafting an alternative treatment guideline for Lyme disease, and advocating against the IDSA Lyme guideline.
The most prominent advocates for ILADS and the existence of chronic Lyme include Dr Fallon (Columbia), and Willy Bergdorfer (Namesake and discoverer of the Lyme bacteria.) Dr. Waisbren is a founding member of IDSA and pro-chronic Lyme, Dr. Auwaerter of Johns Hopkins spoke at an ILADS conference to express the position of the IDSA, and the IDSA guidelines stated it had reviewed scientific data and opinions provided by ILADS.
In 2006 Connecticut attorney general sued the IDSA for antitrust. (Ref) ILADS was a vocal supporter of the suit. (Ref) Although the suit was eventually settled, and the IDSA did not substantially change its guidelines, the state actions against Lyme doctors eventually stopped, and ILADS has slowly built a portfolio of research to back up their opposition to the IDSA guidelines. (Ref)
All three Medical Societies (ILADS, IDSA, GBS) hold medical conventions on Lyme disease around the world.
Patient Activism and the Lyme Loonies
The N.I.H. head of research funding for Lyme disease commented in an email in 2007 his disdain for the “the Lyme loonies.” poughkeepsiejournal He states he received vile, vicious, profane and abusive telephone calls.
It is unlikely that Baker was referring the neuropsychiatric aspects of late stage Lyme disease. Lyme disease: a neuropsychiatric illness However it is observed that Lyme advocates are often working against their own interests with their statements and actions. Controversial treatments and claims are seen across the Internet. New Yorker Michael Specter compares many Lyme advocates unfavorably with early days AIDS activists who were some of the most knowledgeable people in the field. Lyme activists often are associated with conspiracies such as Plum Island (a government bio-warfare that created Lyme), New York Times (they were told not to report on Lyme honestly), N.I.H. (had an agreement with pharmaceutical companies to deny the existence of chronic Lyme disease) New Yorker
The activists have been lumped with other anti-science movements (anti-vaccine and HIV virus deniers) and have been accused of fostering pseudoscientific practices and lobbying for legislation to subvert medicine and science. IDSA guideline authors slam Lyme activists
In response to an unknown document about a Lyme protest at University of Connecticut Health Center in 2007, Professor Durland Fish of Yale University wrote in an email to other IDSA guidelines authors and federal public health officials "This battle cannot be won on a scientific front. We need to mount a socio-political offensive; but we are out-numbered and out-gunned. We need reinforcements from outside our field." Fish emails
Much of the activism stems from the impression that IDSA guidelines were de-facto policies, as insurance coverage was linked to the guidelines, and because doctors fears sanctions for treating outside the guidelines, (ref to Blumenthal) and so expressed their [Political dissent] through protests political lobbying and public opinion. (possible ref Lyme Disease Update: Science, Policy & Law, published by the Lyme Disease Association.)
Other groups have focused on raising money for research, such as XXX and XXX which provided the initial funding if the Columbia University Lyme and Tick-Borne Diseases Research Center, and TBDA which has helped fund research into Lyme biofilms at the University of New Haven, and has funded the training of 125 LLMDs through ILADS.
High cost and low benefit of treating chronic diseases
The care of individuals with chronic conditions is estimated to account for 78% of health expenditures in the United States and insurance companies have begun to target high cost chronic illness for savings. Future work in computerized treatment decision is needed to anticipate doctors overlooking or overprescribing treatments.Multiple Chronic Conditions: Prevalence, Health Consequences, and Implications for Quality, Care Management, and Costs
As early as the 1990's insurance companies used tightened requirements enough to make insurable treatment rare. Insurance companies understood that only certain people would fight for coverage. [2]
Self-treatment trends on the internet
Doctor Patient Relationships and Clinical Diagnosis
The Lyme Wars today
(No References in this section, will come back)
A subculture of LLMDs and Lyme patients has grown up around the internet and patient advocacy groups. For many years patients were careful to protect the names of their physicians. Fringe ideas come from some LLMDs, some advocacy groups, and some patients, and anger and confusion is commonly found on Lyme websites. (OR) However there is also a strong and growing belief within the subculture in both the clinical outcomes, and scientific underpinnings of the LLMD movement. Many LLMDs do not bill insurance companies, and are essentially cash-only clinics. (Ref)
ILADS has trained hundreds of physicians[citation needed] as LLMDs with financial help from donors, and protests by Lyme advocacy groups against the IDSA continue to grow.[citation needed][clarification needed] Mainstream doctors remain reluctant to treat Lyme disease, and the media attention given to the cause of chronic Lyme disease is growing.
The distrust between the two sides remains high, as is evidenced by explicit attacks within medical research and unfounded mutual accusations of corruption and dishonesty. Meanwhile there is a reluctance of doctors to treat Lyme patients, (ref) and despite significant numbers or research papers, almost no change in the treatment of Lyme disease in over a decade. (ref may not be possible, MD fear + unchanged guidance => unchanged treatment)
Meanwhile, the disease rate has steadily increased[citation needed][clarification needed], there is an emerging understanding a large majority of patients go untreated, and that a small percentage of these untreated patients will go on to suffer from a debilitating chronic disease.
Issues to be organized into an introduction
- The high stakes of a major public health emergency.
- The Infectious Diseases Society of America guidelines for treating Lyme disease comparison with 2 minority medical societies
- the refusal of insurance companies to cover treatments not covered by IDSA guidelines (TBD)
- Polarization within the scientific community.
- Patient Advocate Protests
- The effect the war has had on doctors and patients. (TBD)
- Scientific debate on 'chronic Lyme disease' (persistent infection) vs. 'post lyme syndrome' (autoimmune process)
- Newer minority medical associations (International Lyme And Associated Diseases Society, German Borreliosis Society)
- LLMD subculture.
- Training of new LLMDs by ILADS.
- Effectiveness and Safety of long term antibiotic therapy
- Evidence of persistent infection.
- Herxheimer Reaction (amplification of symptoms during antibiotic testing) (TBD)
- Inflammatory cofactors (MTHFR genes, co-infections, diet, nutrients) (TBD)
- Misdiagnosis (TBD)
- the investigation or sanctioning of 50 physicians for prescribing longer term treatment approaches to Lyme disease,
- The anti-trust settlement with the Infectious Diseases Society of America
- State laws to protect patients and physicians from sanctions related to IDSA guidelines.
- Unsupported and Inflammatory Claims on all sides
Controversial Lyme Treatments and Claims
These treatments are not attributable to any medical society. Lyme quackwatch site linked by
- Malariotherapy#Malariotherapy
- Hyperbaric Oxygen Therapy
- Colloidal Silver
- Hydrogen peroxide#Inhalation, Oral administration and Injection
- Bismacine
- Rife machine (<- there is a study pending on this one, and it is an oddly plausible quack)
These claims are not attributable to any medical society. antiscience claims by IDSA panelists.
- Most patients have only subjective symptoms
- Incurable illness when not treated very early
- Causes autism, Morgellon's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, homicidal behaviour, birth defects, and Alzheimer's disease
- Serological testing is of no value in the diagnosis of extracutaneous manifestations of Lyme disease
- IgM testing is appropriate for assessment of patients with illness of long duration
- Serology is less sensitive for detection of Lyme disease in women than in men
The IDSA case against ILADS
http://www.ncbi.nlm.nih.gov/pubmed/21867956
In a 2011 opinion papter Antiscience and ethical concerns associated with advocacy of Lyme disease. by some authors of the IDSA Lyme Guidelines, a strong case is made against Lyme disease advocacy. While it does not distinguish between the [ILADS] and activists in its general claims it describes a parallel universe of pseudoscientific practitioners, research, publications, and meetings.
The specific claims that are attributable to ILADS are:
Current and Former Board Members Disciplinary Actions
- Raphael B. Stricker, MD falsified data on retracted NEJM AIDS paper 1991
- Joeseph Jemsek, MD sanctioned for use of long term antibiotics
- Bernard Raxlen, MD sanctioned prescribed antibiotics for Lyme Disease which are not acceptable for that purpose
- Joseph Burrascano MD sanctioned overdiagnosis/treatment of Lyme Disease
- Richard I. Horowitz sanctioned non-disciplinary action
Use of IGeneX diagnostic tests for Lyme disease
- IGeneX founder Dr. Nick Harris is a co-author of the ILADS treatment guidelines for Lyme disease
- IGeneX products spurred a warning from the US Food and Drug Administration and the CDC about the potential unreliability of unvalidated diagnostic tests for Lyme disease
- IGeneX tests are not compliant with CDC and IDSA standards (April, 2007)
- IGeneX has been the subject of investigations, but is currently compliant.
ILADS past president had prior research that was shoddy
- Steven Phillips, MD 1998 new Lyme culture method was proven to be lethal to Lyme bacteria. 2000 unconventional culture method disproven.
ILADS disagrees with the mainstream view of the scientific evidence
- ILADS supports long term use of antibiotics based on clinical observation on ongoing symptoms.
- IDSA does not see any evidence that the Lyme bacteria persists after proper antibiotic treatment in a human.
Claims By Lyme Doctors
- Charles Ray Jones MD said that 80 percent of his patients are children chronic Lyme disease, some who are blind, paralyzed, or wracked with pain. About 75% are now without symptoms.Hartford Courant article
- Bernard Raxlen, MD says he sees very ill Lyme patients that respond to aggressive long-term antibiotic therapy, "It literally turns their lives around." Chicago Tribune
Terminology used
- Post Lyme Disease Used to denote post treatment symptoms hypothesized to be autoimmune.
- Chronic Lyme Disease Used to denote post treatment or untreated late disease symptoms hypothesized to be due to infection.
- Post-treatment Lyme Disease A compromise term now seen from prominent adherents of both camps.
- Late stage Lyme Disease Usually associated with untreated Lyme disease or with chronic Lyme disease
- Co-infections Used to denote bacterial infections that coexist with Lyme Bacteria.
- Bb name of Lyme Bacteria Borellia Bergdorferi.
- IDSA camp Represents the mainstream medical position, but specifically the authors of the IDSA guidance on the treatment of Lyme disease. Prominently Steere, Wormser, Auwaerter.
- ILADS camp Represents the opposing position, see below on ILADS. Prominently Fallon.
- doctors Represents any physician who is in a position to know the evidence, but generally is seen as working in the mainstream without being outspoken.
- LLMD Represents any physician who self identifies as a Lyme Literate Physician, and should be considered part of the ILADS camp. (Ref needed to LLMD term used in research)
- Borrelia synonymous with Bb
- Borreliosis synonymous with Lyme disease
- neuroborreliosis is Lyme disease with neurological symptoms
- carditis is inflammatory disease of the heart, usually but not exclusively associated with Lyme disease.
Chronic Lyme disease is a large and growing public health crisis.
- The CDC estimates that 300,000 cases of Lyme disease are contracted per year. Only 30,000 confirmed cases are reported to the CDC. CDC Press Release.
- The infection rate is continuing to climb steadily. Reported cases have continued to climb since discovery.
- The quality of life for patients with posttreatment chronic Lyme disease (PTLD) as being equivalent to that of patients with congestive heart failure or osteoarthritis, and their physical impairment was “more than 0.5 SD greater than the impairment observed in patients with type 2 diabetes or a recent myocardial infarction” Klempner trial
- Risk varies by geography Geographic distribution of reported cases of Lyme Disease
- Chronic Lyme has been shown to be a factor in a significant number of cases of Alzheimer's disease. Chronic spirochetal infectionexpert review
- Three sudden deaths of Lyme Carditis is a new report (that is likely to cause ripples because it shows that serious cases are slipping through the cracks: Ripples is my opinion) Three sudden cardiac deaths associated with lyme carditis - United States, november 2012-july 2013.
- Outcomes of Post-treatment Lyme disease are frequently poor. 1994, you already see the divisions between chronic/and post-lyme hypothesis Patients who developed PTLDS had significantly lower life functioning compared to those without PTLDS
- Europe has significantly different strains of the bacteria, but IDSA guidelines are applied across all western countries. The was no European involvement in the IDSA guideline process, and minimal mention of differences in symptomology mentioned in the guidelines (OR).
Evidence of the War in the research archives
- IDSA Camp Bullying Borrelia
- Antiscience and ethical concerns associated with advocacy of Lyme disease.
- Wormser Reply Aug 2013
- Stricker RB, Johnson L.: Chronic Lyme disease: liberation from Lyme denialism Aug 2013
- Halperin JJ, Baker P, Wormser GP: Common misconceptions about Lyme disease
- In your face pro-chronic lyme case report
- Millions of dollars have been spent refuting ILADS claims, and thousands of hours have been spent responding to false allegations, legal threats, congressional queries
the investigation or sanctioning of 50 physicians for prescribing longer term treatment approaches to Lyme disease
NEWS ARTICLE from THE NEW YORK TIMES, 11-10-00, By HOLCOMB B. NOBLE
50 physicians in New York, New Jersey, Connecticut, Michigan, Oregon, Rhode Island and Texas had been investigated, disciplined or had licenses revoked over three years, causing doctors to be reluctant to treat Lyme Disease. (NEWS ARTICLE from THE NEW YORK TIMES, 11-10-00, By HOLCOMB B. NOBLE)
Date | State | Physician | Resolution | Accusation | Notable Involvement |
---|---|---|---|---|---|
DECEMBER 1999 | NY | Dr. Perry Orens | medical license revocation | "rarely if ever" were more than 2-3 weeks of antibiotics were necessary to cure the illness.[2] Ordering excessive tests and/or treatment and inaccurate patient records. gross negligence and fraud. [3] | Dr. Dattwyler (Harvard, ISDA, CDC) Wayne Osten (Director OHSM) |
NY | Joeseph Burrascano | overdiagnosis/treatment of Lyme Disease, Dr. Burrascano's investigation began seven years before the hearing after he testified in Congress against limiting antibiotics for Lyme patients. State inspectors took files of his Lyme patients.[4] OPMC informed him just weeks after the IDSA protocol was first released in late August that they will proceed with their case against him. | Arthur Weinstein (New York Medical College) [5] | ||
April 2006 | NC | Joeseph Jemsek | 1-year medical license suspension with stay [6] | use of intravenous antibiotics for several months outside of recognized standards. not adequately informing patients of departure from recognized standards. | Dr. Brian Fallon testified for Dr. Jemsek (Columbia). Dr. Wormser initiated the complaint [7] |
2002, 2006 | CT, NY | Bernard Raxlen, M.D. | Reprimand (CT), Censure and Reprimand (NY) | prescribed antibiotics for Lyme Disease which are not acceptable for that purpose, poor record keeping, lack of malpractice insurance. NY action is an automatic response to CT action [8] | |
2007 | NY | Richard I. Horowitz, MD | Non-disciplinary action | confidential | confidential |
2007 | CT | Charles Ray Jones, MD | 4 years probation | violating "the applicable standard of care" for his treatment of two young siblings who live in Nevada. The complaint was initiated by the children's father, who is involved in a custody dispute with their mother, an emergency room nurse. After investigating the complaint, the health department brought charges to the medical board, alleging that Jones diagnosed Lyme disease in the children without examining them, that he failed to consider other causes for their symptoms, and that he improperly prescribed antibiotics.[9] | Peter Krause, M.D (Yale, IDSA)[10] |
IDSA antitrust suit
In 2006, Richard Blumenthal, the Connecticut Attorney General, opened an antitrust investigation against the IDSA, accusing the IDSA Lyme disease panel of undisclosed conflicts of interest and of unduly dismissing alternative therapies and chronic Lyme disease. Patients groups led by the California Lyme Disease Association had urged Blumenthal to take this action, however ILADS was also a vocal supporter of Blumenthal's attempted takedown of the IDSA guideline.[3]
The investigation was closed on May 1, 2008, without charges when the IDSA agreed to submit to a review of its guidelines by a panel of independent scientists and physicians which would occur on July 30, 2009.[4] The basis of the lawsuit rested on conflicts of interest that were never publicly exposed. The settlement statement from Blumenthal's settlements mentioned several patient concerns, the use of guidelines to limit patient care because guidelines are treated as mandatory within the medical community, the investigation or sanctioning of 50 physicians for prescribing longer term treatment approaches to Lyme disease, and the refusal of insurance companies to cover treatments not covered by guidelines. [get proper ref to press release http://lymeinfo.wordpress.com/2009/04/13/corrupt-profoundly-flawed-lyme-disease-guidelines/]
The investigation was closed on May 1, 2008, without charges when the IDSA agreed to submit to a review of its guidelines by a panel of independent scientists and physicians which would occur on July 30, 2009.[4] Views on the motivation and outcome of the investigation varied. Blumenthal's press release described the agreement as a vindication of his investigation and repeated his conflict-of-interest allegations.[5]
A Forbes piece described Blumenthal's investigation as "intimidation" of scientists by an elected official with close ties to Lyme advocacy groups.[6] The Journal of the American Medical Association described the decision as an example of the "politicization of health policy" that went against the weight of scientific evidence and may have a chilling effect on future decisions by medical associations.[7]
The medical validity of the IDSA guidelines had not been challenged in the original suit, and in 2010 the IDSA voted to reissued the 2006 guidelines unchanged by a unanimous vote. Cite error: The opening <ref>
tag is malformed or has a bad name (see the help page).
Impact of War on research and treatment
- Texas senator testimony
- Overly restrictive guidelines stifle scientific inquiry Antitrust investigation
- doctors can’t risk losing their licenses charlotte rhino times
Safety of long term use of antibiotics
BELOW ARE UNCHECKED REFERENCES FROM GBS Guidelines demonstrating safety and effectiveness of long term antibiotics.
- CIMMINO, M. A.; ACCARDO, S.: Long term treatment of chronic Lyme arthritis with benzathine penicillin. Ann Rheum Dis 51 (1992), 1007–1008
- CLARISSOU, J.; SONG, A.; BERNEDE, C.; GUILLEMOT, D.; DINH, A.; ADER, F.; PERRONNE, C.; SA- LOMON, J.: Efficacy of a long-term antibiotic treatment in patients with a chronic Tick Associated Poly-Organic Syndrome (TAPOS). Med Mal Infect 39 (2009), 108–115. http://dx.doi.org/10.1016/j.medmal.2008.11.012
- COOPER, C.: Safety of Long Term Therapy with Penicillin and Penicillin Derivatives. FDA, US Food and Drug Administration (2001), Dec. 6. http://www.fda.gov/Drugs/- EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm072755.htm
- DATTWYLER, R. J.; HALPERIN, J. J.; PASS, H.; LUFT, B. J.: Ceftriaxone as effective therapy in refractory Lyme disease. J Infect Dis 155 (1987), 1322–1325
- DONTA, S. T.: Macrolide therapy of chronic Lyme Disease. Med Sci Monit 9 (2003), PI136–PI142
- FALLON, B. A.; KEILP, J. G.; CORBERA, K. M.; PETKOVA, E.; BRITTON, C. B.; DWYER, E.; SLAVOV, I.; CHENG, J.; DOBKIN, J.; NELSON, D. R.; SACKEIM, H. A.: A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70 (2008), 992–1003. http://dx.doi.org/10.1212/01.WNL.0000284604.61160.2d
- GASSER, R.; DUSLEAG, J.: Oral treatment of late borreliosis with roxithromycin plus co- trimoxazole. Lancet 336 (1990), 1189–1190 (
- GASSER, R.; REISINGER, E.; EBER, B.; POKAN, R.; SEINOST, G.; BERGLÖFF, J.; HORWARTH, R.; SE- DAJ, B.; KLEIN, W.: Cases of Lyme borreliosis resistant to conventional treatment – Im- proved symptoms with cephalosporin plus specific beta-lactamase inhibition. Microb Drug Resist 1 (1995), 341–344 (
- KLEMANN, W.; HUISMANS, B.-D.: Patienten mit Erreger-Direktnachweis bei chronischer Lyme-Borreliose – Klinik, Labordiagnostik, Antibiotika-Therapie und Krankheitsver- lauf. Eine retrospektive Studie. Umwelt-Medizin-Gesellschaft 2 (2009), 132–138
- STRICKER, R. B.; GREEN, C. L.; SAVELY, V. R.; CHAMALLAS, S. N.; JOHNSON, L.: Safety of intra- venous antibiotic therapy in patients referred for treatment of neurologic Lyme dis- ease. Minerva Med 101 (2010), 1–7 (
Evidence for and against the use of long term antibiotics for treatment of chronic Lyme disease
The highest quality primary study that showed some effectiveness of antibiotics was done by Fallon. The study showed that the antibiotics were effective until they stopped being used. Fallon is respected by both sides (my opinion) because he was trying to find patients who met the mainstream restricted guidelines for diagnosis and treatment. (Columbia Lyme Center) ILADS Camp primary study often cited by both sides: Fallon, A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy.
Secondary Reviews that state that antibiotics are unwarranted because the benefit did not persist.
- Auwaerter: Point: antibiotic therapy is not the answer for patients with persisting symptoms attributable to lyme disease.
- Wormser: Antibiotic treatment of animals infected with Borrelia burgdorferi.
Secondary Reviews that state that antibiotics may be effective in treating ongoing Lyme infection
- Antibiotic retreatment of Lyme disease in patients with persistent symptoms: a biostatistical review of randomized, placebo-controlled, clinical trials.
- Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with lyme disease.
- Polish journal, Failures of antibiotic treatment in Lyme arthritis
- Fallon: rebuttal and review
Antibiotics and Lyme carditis. Carditis may not be primarily chronic, there is some debate.
- primary case report of cured Lyme carditis with antibiotic therapy.
- secondary review of Lyme Carditis
- Polish journal: hypothesizing chronic Lyme presence: Cardiac manifestations of Lyme borreliosis
Evidence for and against persistent infection (chronic lyme) vs. autoimmune response (post lyme disease)
Secondary reviews that state lack of proof and lack of belief in persistent infection
- There are many. will get to it.
Secondary reviews that support persistent infection
- Review of evidence for immune evasion and persistent infection in Lyme disease
- Borrelia burgdorferi aggrecanase activity: more evidence for persistent infection in Lyme disease
- Proof That Chronic Lyme Disease Exists
Comparisons of treatment guidelines by 3 medical societies
Claim | Infectious Diseases Society of America | International Lyme And Associated Diseases Society | Borreliose-Gesellschaft |
---|---|---|---|
early Lyme symptoms | Erythema migrans rash or neurological Lyme disease or Lyme carditis | 0 | 2 |
late Lyme symptoms | Lyme arthritis or late neurologic Lyme disease especially Bell's Palsy | 0 | 2 |
post treatment symptoms | lack of biologic plausibility, lack of treatment efficacy | 0 | 2 |
post treatment Lyme argument | Risks and adverse effects of antibiotics. Also considered were the inconvenience of prolonged therapies, the potential impact of the indiscriminate use of antibiotics on the development of antibiotic resistance in the community, and the economic costs | 0 | 2 |
Do viable B. burgdorferi persist in tissues despite antibiotic treatment? | There is no convincing evidence in North America for the persistence of B. burgdorferi in the skin of humans after treatment with antibiotic regimens known to be active against B. burgdorferi in vitro. It is highly implausible as evidenced by (1) the lack of antibiotic resistance in this genus, (2) the lack of correlation of persistent symptoms with laboratory evidence of inflammation or with the eventual development of objective physical signs, and (3) the lack of precedent for such a phenomenon in other spirochetal infections. | 0 | 2 |
Acceptable evidence that B. burgdorferi persist in tissues despite antibiotic treatment. | culture should be regarded as the gold standard to address viability of B. Burgdorferi.PCR results cannot prove that B. burgdorferi is viable (i.e. it might be dead or harmless) | 0 | 2 |
Validity of antibody testing. | The panel is unaware of any chronic infection in which antibody titers diminish despite persistence of the causative organism. In syphilis, patients who are regarded as having treatment failure typically have persistent or rising titers of antibodies | 0 | 2 |
characteristics of infections that justify longer treatment courses. | infections in immunodeficient hosts, infections in which a pathogen is inhibited but not killed by antimicrobial therapy or in which available antimicrobials are minimally active in vitro, infections caused by an intracellular pathogen, infections involving a biofilm, infections on a heart valve, or infections involving a clinical site in which there is ischemia, a foreign body, a sequestrum, or frank pus. The “cystic” forms of B. burgdorferi that have been seen under certain growth conditions in vitro have not been shown to have any clinical significance. | 0 | 2 |
Animal studies on persistent infection | failure to recapitulate the T>MIC found in humans receiving antibiotic treatment is a potentially serious limitation of almost all of the reported treatment studies of animals. In other words animals need to get antibiotics more often than humans or else the treatment will fail. Rare animals may remain culture positive after antibiotic treatment. | 0 | 2 |
diagnosis | Two-tier (ELISA and IgG immunoblot) seropositivity or Erythema migrans. Erythema migrans is the only manifestation of Lyme disease in the United States that is sufficiently distinctive to allow clinical diagnosis in the absence of laboratory confirmation. | 0 | 2 |
Chronic Lyme Diagnosis | Not appropriate | 0 | Serological monitoring tests in order to assess the success of treatment are not useful in chronic Lyme borreliosis. The success of treatment must be assessed clinically |
neuroborreolis diagnosis | Two-tier (ELISA and IgG immunoblot) seropositivity plus seropositive lumbar puncture or MRI evidence of neuraxis inflammation | 0 | 2 |
oral antibiotics | 7-21 days | 0 | 2 |
success of oral antibiotics early stage | Less than 10% of individuals do not respond to antibiotic therapy | 0 | A failure rate of 10% is to be expected. Therapeutic success may be delayed or fail to materialise completely, with the consequence that follow-up treatment is necessary, possibly with a different antibiotic. |
success of oral antibiotics post-treatment Lyme | No statistically significant benefit | 30–62% failure with short course treatment. 94% failure in fibromyalgia patients with short course treatment (2-4 weeks) | Considerable therapeutic failure rates when treatment is 4 weeks or less. The duration of treatment is of decisive importance for the success of antibiotic treatment. a failure rate of up to 50%. |
IV Antibiotics | 14-28 days. intravenous administration should only rarely be needed. | 0 | 2 |
success of IV antibiotics | 0 | doubling treatment time from 2 to 4 weeks improved the success rate from 66 to 80% | |
co-infections | Simultaneous infections are rare, but other infections may clinically appear similar to Lyme. HGA, babesiosis, A. phagocytophilum, A. phagocytophilum or B. microti | 0 | 2 |
erythema migrans | The great majority of persons with B. burgdorferi infection present with erythema migrans | 0 | 2 |
Prevelance | 0%–4.6% of ticks have bB. | 0 | 2 |
Regions of infection | New England, in parts of the mid-Atlantic States, and in parts of Minnesota and Wisconsin, but not in most other locations of the United States. Southern ticks are rarely infected with B. burgdorferi. | 0 | 2 |
Incidence | Because most patients with Lyme disease are now diagnosed and treated early in the course of infection, (late Lyme) forms of neurologic Lyme disease are quite rare | 0 | 2 |
1 000 000 | 18 488 885 | 18 488 874 |
Evidence of Physician Practices
With competing guidelines, studies have shown various rates of agreement and compliance with the dominant medical position, the IDSA guidelines.
- Doctors bucking Lyme Protocols
- 1994 study of doctors aggressive treatments
- 1996 study saying 57% of doctors prescribe antibiotics for more than 3 months for Lyme
- Pro-IDSA 2011 study shows 53% of doctors think chronic Lyme does not exist
UNVERIFIED REFERENCES IN ILADS TREATMENT GUIDEDLINES SHOWING DOCTORS USE LONG TERM ANTIBIOTICS
- Feder HM Jr. Differences are voiced by two Lyme camps at a Connecticut public hearing on insurance coverage of Lyme disease. Pediatrics 105(4 Pt 1), 855–857 (2000).
- Fallon BA, Tager F, Keilp J, Weiss N, Liebowitz MR, Fein L, Liegner K. Repeated antibiotic treatment in chronic Lyme disease. J. Spiro Tick Dis. 6, 94–102 (1999).
- Battaglia HR, Alvarez G, Mercau A, Fay M, Campodónico M. Psychiatric symptomatology associated with presumptive Lyme disease: clinical evidence. J. Spirol. Tick Dis. 7, 22–25 (2000).
- Fallon BA. Chronic Lyme Disease Research Study. A double-blind placebo-controlled randomized clinical trial evaluating the efficacy of tenweeks of iv. ceftriaxone and effects on brain imaging. Enrollment since 2000.
- Cameron DJ. Lyme Disease Retreatment Study. A double-blind placebo-controlled randomized clinical trial evaluating the efficacy of oral amoxicillin for seropositive and seronegative Lyme disease. Enrollment since 2001.
- Peña CA, Mathews AA, Siddiqi NH, Strickland GT. Antibiotic therapy for Lyme disease in a population-based cohort. Clin. Infect. Dis. 29, 694–695 (1999).
- Wahlberg P, Granlund H, Nyman D, Panelius J, Seppala I. Treatment of late Lyme borreliosis. J. Infect. 29, 255–261 (1994).
- Donta ST. Tetracycline therapy for chronic Lyme disease. Clin. Infect. Dis. 25(Suppl. 1), S52–S56 (1997).
Lyme Literate Physician (LLMD) Training
125 physicians have completed a three week course that included ILADS class room studies, and a week working alongside the most experienced LLMDs.TBDA LLMD Training
How many has ILADS trained???
Chronic Lyme Diagnosis and Treatment
Unsupported and Inflammatory Claims
- The Government created Lyme disease at Plum Island, NY
- UnderOurSkin has good points but many inaccuracies and is highly inflammatory (OR)
- Financial conflicts of interest within the IDSA Lyme guidance group.
- Fee based specialty Lyme clinics and labs are parasites. Forbes anti-chronic Lyme article
Chronic Lyme and LLMDs in RS Media
- Forbes 2007 anti-chronic Lyme
- New Yorker 2013 pro-chronic Lyme
- Boston Herald Story of ILADS founding [8]
- 2013 pro-chronic Lyme video Poughkeepsie Journal
- 2013 Poughkeepsie Journal, “Chronic Lyme disease: Is it real? Officials say no, but some patients say yes – and demand a say” by Mary Beth Pfeiffer
- NYTIMES
- Under Our Skin Vanity Fair Review [11] "partisan, manipulative, and prone to conspiracy" (The Lancet Infectious Diseases)
- Chicago Tribune 2010 anti-chronic Lyme
Geographic distribution And time series of evolving neurological diseases
- lyme us distribution
- Multiple Sclerosis us distribution
- Schitzophrenia us distribution
- autism us distribution
- Autism rate time series
- Lyme rate time series.
- Diseases not showing significant age adjusted changes over time: schizophrenia, Alzheimer's, Multiple Sclerosis, ADHD
Public cases of chronic lyme
- Forbes/JPMorgan, note a key person was out of work with Lyme and returned after 1-2 years.
- David Roth - runs $100B+ real estate fund - highlighted in New Yorker article
- Amy Tan author story
Below are references to look into....
- Alice Walker Pulitzer prize winning author
- David Letterman
- Yolanda Foster
Patient Advocacy Organizations
- The Lyme Disease Network : Pro-Chronic Lyme Education and Prevention
- American Lyme Disease Foundation : Anti-Chronic Lyme Education and Prevention
- Pro-Chronic Lyme Lyme Disease Support Network
Research Organizations
- Lyme Disease Association : Co-founded the Columbia Lyme Center
- Lyme Research Alliance, Formerly Time for Lyme : Co-founded the Columbia Lyme Center
- The Lyme Disease Foundation (LDF)
- LymeMD : Research
- Tick Borne Disease Association Biofilm research and LLMD training
Protests
Kenneth B. Liegner, MD (need better link)
ILADS
The International Lyme And Associated Diseases Society (ILADS, pronounced /ˈaɪlædz/) is a medical society and advocacy group which advocates for greater acceptance of the controversial medical entity of chronic Lyme disease and argue that the traditional approach to diagnosis and treatment, put forth by most American physicians, all but guarantees failure.[9]
Background
Lyme disease is not well understood, can not be reliably detected, and sometimes has serious long term symptoms that are resistant to treatment. [references probably fallon, and others] It is reported that 300,000 people contract the disease each year, but only 10% of that number are reported to the CDC as diagnosed cases of Lyme. [CDC reference]. Since the day the disease was discovered in 1978 through today there are a large number of untreated cases of Lyme disease, as well as cases of treated Lyme disease that continued to have serious symptoms. Late stage Lyme disease can have symptoms similar to many other diseases, such as multiple sclerosis, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome, lupus, Crohn's disease, HIV or other autoimmune and neurodegenerative diseases.
The "Lyme Wars" grew steadily through the 1980s and 1990s as increasing populations of people presented themselves to doctors with clinical symptoms of Lyme disease and doctors began using longer doses of antibiotics. Allen Steere wrote in 1993, that Lyme disease had become "overdiagnosed" and overtreated.[10]. Clinical diagnosis in medicine is not rare, but infectious diseases are very hard to treat with out objective evidence that an infection is actively causing disease. [made this up, may need to drop.]
ILADS was founded in 1999 by physicians and academics who believe mainstream medicine is too conservative in its treatment of Lyme. Some of those physicians had been treating Lyme disease for two decades. [3] The same year saw the first protests by Lyme patient activist against Allen Steere due to concerns his treatment guidelines were causing insurance companies to refuse coverage. The protesters claimed that Dr. Steere's testimony against their doctors before medical licensing boards had caused some of them to stop giving aggressive treatments. [11]
Doctors who are members of ILADS, or who have been trained by them are often known as "Lyme literate Medical doctors." or LLMD's.
2000 IDSA Guidelines
In 2000, The Infectious Diseases Society of America published their Practice guidelines for the treatment of Lyme disease. [Clean ref needed for (Clin Infect Dis 2000; 31[Suppl 1]:1–14).] In those guidelines, IDSA stated that there was no convincing evidence for the existence of chronic symptomatic B. burgdorferi infection, and that the risks of long-term antibiotic therapy do not outweigh the benefits.
ILADS criticized the IDSA for ignoring the "compelling, peer-reviewed, published evidence" of chronic Lyme disease, and ultimately published their own guidelines formulated from scientific evidence in 2006.[3]
Doctor/Patient Advocacy
ILADS was (and remains) active in getting state laws passed that explicitly allow the use of long term antibiotics in the treatment of Lyme disease.[3] The states of Connecticut[12]Rhode Island[13] California[14] Massachusetts[15] and New Hampshire[16] have such laws. Advocacy is continuing in Connecticut, Pennsylvania and Virginia [17]
The [Association of American Physicians and Surgeons] (AAPS) worked with the ILADS to criticize the IDSA Lyme guidelines with the goal of fostering private, physician-patient centered medicine. AAPS spokesperson Jane Orient, MD, said, "Those doctors have been viciously attacked, even by their own medical boards and by the societies that consider themselves the only source of expertise. Insurance companies are behind this because they don't want to pay for the treatment. Long-term antibiotics can be very expensive." [3]
The 2006 IDSA Treatment Guidance and 2006 ILADS Treatment Guidance
In 2006 updated treatment guidance was published by the IDSA, and at approximately the same time the ILADS published their first treatment guidance based on a review of the scientific evidence.
The majority of physicians support the IDSA guidelines, and prior to 2006 ILADS had limited its role to criticizing the IDSA guidelines. The 2006 Report [18] in 2007 many of the authors of the IDSA guidance published a paper highly critical of the use of long-term antibiotics in the treatment of Lyme Disease. [19] In this paper they clearly state that the term "chronic Lyme disease" is not recognized in the medical literature and specifically identify the small number of self described "Lyme literate physicians" who treat patients who have no objective evidence that they have been infected with Lyme. ILADS guidelines do support clinically diagnosis of Lyme, as they claim serological tests are unreliable.
The established medical opinion is that there are no scientific studies that show any connection between the clinic symptoms and Lyme bacteria, and as a result the ILADS guidelines were causing a number of serious ailments to be mistreated as Lyme, which is both unethical and dangerous. It is recommended that patients who show symptoms similar to late stage Lyme, but who have been treated should only be given palliative care, as other treatment will be unsuccessful and give false hope.[19]
ILADS disagrees, and a minority of doctors does treat chronic Lyme disease based on a clinical diagnosis with long term antibiotics and gives evidence that many (but not all) improve [show ref here.]
A crucial and unanswered question is whether Lyme bacteria can survive antibiotic treatment and remain viable as a pathogen, or if the few people who remain sick after treatment are simply experiencing an autoimmune reaction to the initial infection that eventually clears.[wormser ref, fallon or ny post ref]
doctors associated with the (IDSA)state that no viable Lyme bacteria exists in a human after a short course of antibiotics. Several mice and primate studies have seemed to show that bacteria survives exposure to antibiotics, however there are questions about whether the bacteria was viable, how well the study was implements, and its applicability to humans. [Wormser rebuttal] It is generally believed that dead bacteria generate a autoimmune response, and this has been demonstrated by detecting Lyme antigens after treatment cleared the bacteria. [See Yale mouse antigen study.] This study too was challenged for failing to prove the bacteria was not longer viable when the antigens were detected. [McDonald ref].
The minority believes that numerous animal studies have shown that the Lyme bacteria very quickly establishes itself in the body in a way that protects in from antibiotics. Lyme bacteria has been shown to colonize into biofilms that have significant protection against bacteria. [ref]
IDSA antitrust suit
In 2006, Richard Blumenthal, the Connecticut Attorney General, opened an antitrust investigation against the IDSA, accusing the IDSA Lyme disease panel of undisclosed conflicts of interest and of unduly dismissing alternative therapies and chronic Lyme disease. Patients groups led by the California Lyme Disease Association had urged Blumenthal to take this action, however ILADS was also a vocal supporter of Blumenthal's attempted takedown of the IDSA guideline.[3]
The investigation was closed on May 1, 2008, without charges when the IDSA agreed to submit to a review of its guidelines by a panel of independent scientists and physicians which would occur on July 30, 2009.[4] The basis of the lawsuit rested on conflicts of interest that were never publicly exposed. The settlement statement from Blumenthal's settlements mentioned several patient concerns, the use of guidelines to limit patient care because guidelines are treated as mandatory within the medical community, the investigation or sanctioning of 50 physicians for prescribing longer term treatment approaches to Lyme disease, and the refusal of insurance companies to cover treatments not covered by guidelines. [get proper ref to press release http://lymeinfo.wordpress.com/2009/04/13/corrupt-profoundly-flawed-lyme-disease-guidelines/]
The investigation was closed on May 1, 2008, without charges when the IDSA agreed to submit to a review of its guidelines by a panel of independent scientists and physicians which would occur on July 30, 2009.[4] Views on the motivation and outcome of the investigation varied. Blumenthal's press release described the agreement as a vindication of his investigation and repeated his conflict-of-interest allegations.[5]
A Forbes piece described Blumenthal's investigation as "intimidation" of scientists by an elected official with close ties to Lyme advocacy groups.[6] The Journal of the American Medical Association described the decision as an example of the "politicization of health policy" that went against the weight of scientific evidence and may have a chilling effect on future decisions by medical associations.[7]
The medical validity of the IDSA guidelines had not been challenged in the original suit, and in 2010 the IDSA voted to reissued the 2006 guidelines unchanged by a unanimous vote. Cite error: The opening <ref>
tag is malformed or has a bad name (see the help page).
ILADS Annual Lyme Disease Conference
Since 2000 ILADS has held an annualLyme Disease Conference to promote research and training in the treatment of Lyme disease including chronic Lyme disease.
The 2013 Lyme Disease Conference was held in San Diego Oct 17-19 2013. The conference had 420 attendees and 32 speakers.
Notable Past speakers have included:
- Willy Bergdorfer, who discovered the Lyme Bacteria (Keynote speaker 2008)
- Brian Fallon, Director of the Columbia University Lyme and Tick-Borne Diseases Research Center (2012)
- Paul Auwaerter, MD, (Current Director of Infectious Diseases and Professor at Johns Hopkins University) Treatment: the IDSA Perspective. (2007)
- Eva Sapi, PhD, (Discovered Lyme bacteria biofilm antibiotic resistance). (2013)
Physician Training
- section on the hundreds (or thousand) LLMDS trained by ILADS
Columbia
- Section on Columbia Lyme center as an organization that does collaborative work in chronic lyme
Both sets of doctors are practicing medicine in a reasonable fashion based on the application of certain diagnostic principles, although the therapeutic approaches differ considerably stemming from the narrow vs broad criteria for diagnosis. This is the essence of the medical controversy surrounding chronic Lyme disease. Until medical doctors have a test that definitively identifies the presence or absence of infection (and such a test does not yet exist), the controversy about the diagnosis and treatment of chronic Lyme Disease will continue. [mfix this]
Borreliose-Gesellschaft
- Section on group similar to ILADS in europe
German Chronic Lyme Guidelines you will see that the Deutsche Borreliose-Gesellschaft,
David Roth
- Prominent activist funding ILADS LLMD training and Eva Sapi research. The heading will be the name of his organization, not him.
In the media
Pro LLMD article in New Yorker anti LLMD article in Forbes One or two other recent and well researched articles. I can't skip under-my-skin, it is too big, hope to find debunking sources.
Criticisms of ILADS
- IDSA had some specific harsh words about some past practices
- There may or may not be some sources on some of the fringe element within IDSA that is well sourced.
References
- ^ Steere AC, Taylor E, McHugh GL, Logigian EL (1993). "The overdiagnosis of Lyme disease". JAMA. 269 (14): 1812–6. doi:10.1001/jama.269.14.1812. PMID 8459513.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Science journalist Pamela Weintraub reported details of Supreme Court of the State of New York hearing in a chapter titled “Red-Flagged at Blue Cross: The Role of Managed Care” in her book “Cure Unknown: Inside the Epidemic.” (pp. 303-306)
- ^ a b c d e f {{cite news } work = MedPage Today | first=Nancy | last=Walsh | url=http://www.medpagetoday.com/PublicHealthPolicy/GeneralProfessionalIssues/23583 | date = November 26, 2000 | accessdate = December 30, 2013}}
- ^ a b c d Cite error: The named reference
amnews
was invoked but never defined (see the help page). - ^ a b Cite error: The named reference
ct_ag_2008
was invoked but never defined (see the help page). - ^ a b Cite error: The named reference
forbes
was invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Kraemer_2009
was invoked but never defined (see the help page). - ^ {{cite news } work = Boston Herald | first=Michael | last= Lasalandra| url=http://www.medpagetoday.com/PublicHealthPolicy/GeneralProfessionalIssues/23583 | date = November 3, 1999 | accessdate = December 30, 2013}}
- ^ Specter, Michael (July 1, 2013). "Lyme, Inc". New Yorker. Retrieved December 30, 2013.
- ^ Steere AC, Taylor E, McHugh GL, Logigian EL (1993). "The overdiagnosis of Lyme disease". JAMA. 269 (14): 1812–6. doi:10.1001/jama.269.14.1812. PMID 8459513.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ {{cite news } work = Boston Herald | first=Michael | last= Lasalandra| url=http://www.medpagetoday.com/PublicHealthPolicy/GeneralProfessionalIssues/23583 | date = November 3, 1999 | accessdate = December 30, 2013}}
- ^ "An act concerning the use of long-term antibiotics for the treatment of Lyme disease". Connecticut General Assembly. 2009-06-18. Retrieved 2009-07-05.
- ^ "Lyme Disease and the Law". Rhode Island Department of Health. 2009. Archived from the original on May 2, 2005. Retrieved 2009-07-05.
- ^ California Business and Professions, Section 2234.1, AB 592, passed August 29, 2005.ftp://leginfo.public.ca.gov/pub/05-06/bill/asm/ab_0551-0600/ab_592_bill_20050831_enrolled.pdf
- ^ Section 12DD Administration of long-term antibiotic therapy upon diagnosis of Lyme disease MGL Chapter 112 Section 12DD (2010)
- ^ "New Hampshire General Court, HB 295, approved June 9, 2011". Gencourt.state.nh.us. Retrieved 2012-12-15.
- ^ {{>
{{cite web}}
: Empty citation (help) - ^ "2006 ILADS Treatment Guidelines" (PDF).
- ^ a b Feder, HM; Johnson, BJB; O'Connell, S; et al. (2007). "A Critical Appraisal of "Chronic Lyme Disease"" (PDF). NEJM. 357 (14): 1422–30. doi:10.1056/NEJMra072023. PMID 17914043.
{{cite journal}}
: Unknown parameter|month=
ignored (help)
External links